Selleck Chemicals supplies over 3,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors.
Company WebsiteTegaserod Maleate(HTF-919) is a hydrogen maleate salt form of tegaserod, which is a 5-HT4 receptor partial agonist and binds with high affinity to 5-HT4 receptors. It has limited affinity for 5-HT1 receptors and no appreciable affinity for other 5-HT receptors, muscarinic, adrenergic, dopaminergic or opiate receptors.
More Information Supplier PageTegaserod Maleate(HTF-919) is a hydrogen maleate salt form of tegaserod, which is a 5-HT4 receptor partial agonist and binds with high affinity to 5-HT4 receptors. It has limited affinity for 5-HT1 receptors and no appreciable affinity for other 5-HT receptors, muscarinic, adrenergic, dopaminergic or opiate receptors.
More Information Supplier PageTegatrabetan (BC2059,Tegavivint) is an antagonist of β-Catenin. Tegatrabetan (BC2059) treatment disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1) and proteasomal degradation and declines in the nuclear levels of β-catenin.
More Information Supplier PageTegatrabetan (BC2059,Tegavivint) is an antagonist of β-Catenin. Tegatrabetan (BC2059) treatment disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1) and proteasomal degradation and declines in the nuclear levels of β-catenin.
More Information Supplier PageTegatrabetan (BC2059,Tegavivint) is an antagonist of β-Catenin. Tegatrabetan (BC2059) treatment disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1) and proteasomal degradation and declines in the nuclear levels of β-catenin.
More Information Supplier PageTegatrabetan (BC2059,Tegavivint) is an antagonist of β-Catenin. Tegatrabetan (BC2059) treatment disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1) and proteasomal degradation and declines in the nuclear levels of β-catenin.
More Information Supplier PageTegatrabetan (BC2059,Tegavivint) is an antagonist of β-Catenin. Tegatrabetan (BC2059) treatment disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1) and proteasomal degradation and declines in the nuclear levels of β-catenin.
More Information Supplier PageTegobuvir (TGV, GS 333126, GS-9190) is a non-nucleoside inhibitor of HCV RNA replication with proven antiviral activity in HCV-infected patients.
More Information Supplier PageTegoprazan (CJ-12420, IN-A001, K-CAB, LXI-15028, RQ-00000004) is a novel potent and highly selective inhibitor of gastric H+/K+-ATPase with IC50s ranging from 0.29 μM to 0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro, respectively.
More Information Supplier PageTeicoplanin (Teichomycin,Targocid,MDL-507) is a glycopeptide antibiotic, used to treat serious infections caused by Gram-positive bacteria.
More Information Supplier PageTeicoplanin (Teichomycin,Targocid,MDL-507) is a glycopeptide antibiotic, used to treat serious infections caused by Gram-positive bacteria.
More Information Supplier PageTelacebec is a novel antituberculosis drug that targets Mycobacterium tuberculosis cellular energy production through inhibition of the mycobacterial cytochrome bc1 complex. Telacebec (Q203, IAP6) is active against Mycobacterium tuberculosis H37Rv with MIC50 of 2.7 nM in culture broth medium.
More Information Supplier PageTelacebec is a novel antituberculosis drug that targets Mycobacterium tuberculosis cellular energy production through inhibition of the mycobacterial cytochrome bc1 complex. Telacebec (Q203, IAP6) is active against Mycobacterium tuberculosis H37Rv with MIC50 of 2.7 nM in culture broth medium.
More Information Supplier PageTelacebec is a novel antituberculosis drug that targets Mycobacterium tuberculosis cellular energy production through inhibition of the mycobacterial cytochrome bc1 complex. Telacebec (Q203, IAP6) is active against Mycobacterium tuberculosis H37Rv with MIC50 of 2.7 nM in culture broth medium.
More Information Supplier PageTelaglenastat (CB-839) is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. CB-839(Telaglenastat) inudces autophagy and has antitumor activity. Phase 1.
More Information Supplier PageTelaglenastat (CB-839) is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. CB-839(Telaglenastat) inudces autophagy and has antitumor activity. Phase 1.
More Information Supplier PageTelaglenastat (CB-839) is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. CB-839(Telaglenastat) inudces autophagy and has antitumor activity. Phase 1.
More Information Supplier PageTelaglenastat (CB-839) is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. CB-839(Telaglenastat) inudces autophagy and has antitumor activity. Phase 1.
More Information Supplier PageTelaglenastat (CB-839) is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. CB-839(Telaglenastat) inudces autophagy and has antitumor activity. Phase 1.
More Information Supplier PageTelaprevir is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μM.
More Information Supplier PageTelaprevir is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μM.
More Information Supplier PageTelaprevir is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μM.
More Information Supplier PageTelatinib (BAY 57-9352) is a potent inhibitor of VEGFR2/3, c-Kit and PDGFRα with IC50 of 6 nM/4 nM, 1 nM and 15 nM, respectively. Phase 2.
More Information Supplier PageTelatinib (BAY 57-9352) is a potent inhibitor of VEGFR2/3, c-Kit and PDGFRα with IC50 of 6 nM/4 nM, 1 nM and 15 nM, respectively. Phase 2.
More Information Supplier PageTelazorlimab (Anti-TNFRSF4 / OX40 / CD134) is a humanized monoclonal antibody against the OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for research on autoimmune diseases. MW : 145.5 KD.
More Information Supplier PageTelazorlimab (Anti-TNFRSF4 / OX40 / CD134) is a humanized monoclonal antibody against the OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for research on autoimmune diseases. MW : 145.5 KD.
More Information Supplier PageTelazorlimab (Anti-TNFRSF4 / OX40 / CD134) is a humanized monoclonal antibody against the OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for research on autoimmune diseases. MW : 145.5 KD.
More Information Supplier PageTelbivudine(NV 02B) is a potent, and selective HBV reverse transcriptase inhibitor, used to treat HBV infection.
More Information Supplier PageTelisotuzumab (Anti-HGFR / c-Met) is a monoclonal antibody that targets c-Met. MW: 145.64 KD.
More Information Supplier PageTelisotuzumab (Anti-HGFR / c-Met) is a monoclonal antibody that targets c-Met. MW: 145.64 KD.
More Information Supplier PageTelisotuzumab (Anti-HGFR / c-Met) is a monoclonal antibody that targets c-Met. MW: 145.64 KD.
More Information Supplier PageTelisotuzumab vedotin (Teliso-V, ABBV-399) is an antibody-drug conjugate (ADC) composed of the anti–c-Met humanized monoclonal antibody coupled to the cytotoxic monomethyl auristatin E (MMAE) through a mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used for research on advanced solid tumours.
More Information Supplier PageTelisotuzumab vedotin (Teliso-V, ABBV-399) is an antibody-drug conjugate (ADC) composed of the anti–c-Met humanized monoclonal antibody coupled to the cytotoxic monomethyl auristatin E (MMAE) through a mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used for research on advanced solid tumours.
More Information Supplier PageTelithromycin is a ketolide antibiotic to treat community acquired pneumonia of mild to moderate severity.
More Information Supplier PageTelithromycin is a ketolide antibiotic to treat community acquired pneumonia of mild to moderate severity.
More Information Supplier PageTelmisartan (BIBR 277) is an angiotensin II receptor antagonist (ARB) used in the management of hypertension.
More Information Supplier PageTelotristat Etiprate (LX 1606 Hippurate) is an orally bioavailable, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity. Phase 3.
More Information Supplier PageTelotristat Etiprate (LX 1606 Hippurate) is an orally bioavailable, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity. Phase 3.
More Information Supplier PageTelratolimod (3M-052, MEDI9197) is an agonist of toll-like receptor 7 (TLR-7) and toll-like receptor 8 (TLR-8) with antitumor activity.
More Information Supplier PageTelratolimod (3M-052, MEDI9197) is an agonist of toll-like receptor 7 (TLR-7) and toll-like receptor 8 (TLR-8) with antitumor activity.
More Information Supplier PageTelratolimod (3M-052, MEDI9197) is an agonist of toll-like receptor 7 (TLR-7) and toll-like receptor 8 (TLR-8) with antitumor activity.
More Information Supplier PageTemocapril (CS-622,temocaprilum) is a long-acting angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension.
More Information Supplier PageTemocapril HCl (CS-622) is the hydrochloride of Temocapril, which is a long-acting angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension.
More Information Supplier PageTemozolomide acid is a carboxylic acid derivative of Temozolomide. It has an anticancer activity by causing breaks in DNA double strand, cell cycle arrest, and eventually cell death.
More Information Supplier PageTemozolomide acid is a carboxylic acid derivative of Temozolomide. It has an anticancer activity by causing breaks in DNA double strand, cell cycle arrest, and eventually cell death.
More Information Supplier PageTempol (4-Hydroxy-TEMPO) is a superoxide scavenger that displays neuroprotective, anti-inflammatory and analgesic effects. Phase 2.
More Information Supplier PageTempol (4-Hydroxy-TEMPO) is a superoxide scavenger that displays neuroprotective, anti-inflammatory and analgesic effects. Phase 2.
More Information Supplier PageTemsavir (BMS-626529) is a novel small-molecule HIV-1 attachment inhibitor active against both CCR5- and CXCR4-tropic viruses.
More Information Supplier PageTemsirolimus is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay. Temsirolimus induces autophagy and apoptosis.
More Information Supplier PageTemsirolimus is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay. Temsirolimus induces autophagy and apoptosis.
More Information Supplier Page
